Management of severe hidradenitis suppurativa with biologic therapy and wide excision

6Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.

Cite

CITATION STYLE

APA

Lim, S. Y. D., Cheong, E. C., & Oon, H. H. (2019). Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Archives of Plastic Surgery, 46(3), 272–276. https://doi.org/10.5999/aps.2018.00339

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free